RecruitingPhase 2NCT05029336

Autologous Stem Cell Transplant (ASCT) for Autoimmune Diseases

Autologous Hematopoietic Stem Cell Transplant for Children and Young Adults With Life Threatening Autoimmune Diseases

Sponsor

Stephan Grupp MD PhD

Enrollment

20 participants

Start Date

Mar 1, 2026

Study Type

INTERVENTIONAL

Conditions

Systemic Lupus Erythematosus Systemic Sclerosis

Summary

A subset of autoimmune diseases (ADs) in children and young adults are life-threatening and unresponsive to conventional treatments. In these patients, the delivery of high dose immunosuppressive therapy followed by autologous stem cell transplant (ASCT) offers a treatment strategy capable of purging the pathogenic, autoreactive immune system and an opportunity for "immune reset." This strategy has been used in adults across a myriad of indications with evidence for efficacy. This study proposes a pilot study to evaluate this therapeutic strategy in children and young adults with systemic sclerosis (SSc) and systemic lupus erythematosis (SLE), two potentially life threatening autoimmune diseases that may response to this therapeutic approach.

Eligibility

Min Age: 8 YearsMax Age: 25 Years

Inclusion Criteria4

Age 8 ≤ 25 years at time of enrollment.
Severe systemic sclerosis or systemic lupus erythematosus based on specific criteria
Adequate organ function status
No active, untreated infections.

Exclusion Criteria4

Previous hematopoietic stem cell transplant (HSCT) or solid organ transplant
Pregnancy
Ongoing participation in a clinical trial testing an investigational drug or ongoing receipt of disallowed disease modifying anti-rheumatic drugs (DMARD)
Severe comorbidity that jeopardizes the ability of the subject to tolerate therapy

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

BIOLOGICALDepletion of CD3/CD19 in an autologous stem cell transplant

The purpose of this study is to determine the safety and feasibility of CD3/CD19 depleted autologous stem cell transplant for the treatment of life threatening autoimmune disease. We will perform CD3/CD19 depletion using the CliniMACs device as a means of purging autoreactive T and B cells from the transfused autologous stem cell product, while retaining some immune function, namely natural killer cells and monocytes in the product.